CME Group (CME) Stock Forecast & Price Target

$224.43

+0.16 (+0.07%)

(As of 10/4/2024 ET)

CME Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 13 Analyst Ratings

Sell
4

Hold
6

Buy
3

Based on 13 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 13 analysts, 4 have given a sell rating, 6 have given a hold rating, and 3 have given a buy rating for CME.

Consensus Price Target

$213.77
-4.75% Downside

According to the 13 analysts' twelve-month price targets for CME Group, the average price target is $213.77. The highest price target for CME is $250.00, while the lowest price target for CME is $180.00. The average price target represents a forecasted downside of -4.75% from the current price of $224.43.

Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

CME Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	6 Buy rating(s)
Hold	6 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	4 Sell rating(s)	4 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$213.77	$209.73	$215.90	$211.55
Forecasted Upside	-4.75% Downside	-4.89% Downside	10.73% Upside	-0.18% Downside
Consensus Rating	Reduce	Reduce	Reduce	Moderate Buy

How much money are you leaving on the table from the stocks you already own? (Ad)

Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash flow. Simply put, this time-tested 3-step strategy allows anyone to create cash flow from the stocks you already own without selling a single share in your portfolio. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.

CLICK HERE TO RSVP

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CME Group Stock vs. The Competition

Type	CME Group	Finance Companies	S&P 500
Consensus Rating Score	1.92	2.47	2.50
Consensus Rating	Reduce	Hold	Moderate Buy
Predicted Upside	-4.75% Downside	14.92% Upside	7.04% Upside
News Sentiment Rating	Positive News See Recent CME News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/3/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$240.00 ➝ $250.00	+11.29%
10/3/2024	The Goldman Sachs Group 2 of 5 stars		Boost Target	Sell ➝ Sell	$195.00 ➝ $198.00	-11.89%
10/3/2024	Royal Bank of Canada 4 of 5 stars	A. Sabadra Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$235.00 ➝ $235.00	+4.16%
10/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$177.00 ➝ $180.00	-19.49%
9/26/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Katz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$221.00	+1.60%
8/20/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$225.00 ➝ $225.00	+7.56%
Get the Latest News and Ratings for CME and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CME Group and its competitors with MarketBeat's FREE daily newsletter.
8/15/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$193.00 ➝ $200.00	-2.59%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$187.00 ➝ $191.00	-3.65%
7/25/2024	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$212.00 ➝ $213.00	+7.98%
7/25/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$208.00 ➝ $209.00	+5.96%
4/25/2024	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Sell ➝ Sell	$185.00 ➝ $187.00	-12.04%
4/9/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$222.00 ➝ $225.00	+6.53%
3/6/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$225.00 ➝ $245.00	+12.27%
4/12/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$213.00 ➝ $221.00	+15.26%
2/7/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$192.00 ➝ $198.00	+13.30%
1/5/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$226.00 ➝ $220.00	+29.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:38 PM ET.

Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 29, 2024. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

Here are some ways that investors could benefit from investing in CME Group Inc.:

CME Group Inc. has consistently shown strong earnings per share (EPS) performance, with a forecasted EPS of 9.94 for the current year, indicating financial stability and potential growth.
The company has a solid dividend payout ratio of 52.33%, offering investors a steady income stream through quarterly dividends.
Institutional investors have been increasing their holdings in CME Group Inc., signaling confidence in the company's future prospects and stability.
Recent analyst reports have provided positive ratings and target price upgrades for CME Group Inc., suggesting a favorable outlook from Wall Street analysts.
CME Group Inc. operates contract markets for trading futures and options globally, providing diversified investment opportunities in the financial services sector.

CME Group
Bear Case

Investors should be bearish about investing in CME Group Inc. for these reasons:

Some analysts have issued sell ratings for CME Group Inc., indicating potential concerns about the company's performance or market conditions.
There have been insider selling activities within CME Group Inc., such as Director Bryan T. Durkin selling shares, which may raise questions about insider confidence in the company.
One analyst downgraded CME Group Inc. from a "neutral" rating to an "underperform" rating, suggesting a less optimistic view on the company's future performance.
Despite positive aspects, CME Group Inc. faces competition and regulatory challenges in the financial services industry, which could impact its growth and profitability.
Market conditions and economic uncertainties can influence the performance of CME Group Inc.'s stock price, leading to potential volatility in investment returns.

CME Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $213.77, with a high forecast of $250.00 and a low forecast of $180.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" CME shares.
: According to analysts, CME Group's stock has a predicted downside of -4.75% based on their 12-month stock forecasts.
: Over the previous 90 days, CME Group's stock had 1 downgrade by analysts.
: CME Group has been rated by research analysts at Bank of America, Barclays, Citigroup, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Piper Sandler, Royal Bank of Canada, TD Cowen, and The Goldman Sachs Group in the past 90 days.
: Analysts like CME Group less than other "finance" companies. The consensus rating for CME Group is Reduce while the average consensus rating for "finance" companies is Hold. Learn more on how CME compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

This page (NASDAQ:CME) was last updated on 10/6/2024 by MarketBeat.com Staff

From Our Partners